AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
AbbVie(ABBV) stock is priced at $219.93, giving the company a market capitalization of 382.65B. It carries a P/E multiple of 106.78 and pays a dividend yield of 3.11%.
As of 2026-06-22, AbbVie(ABBV) stock has fluctuated between $218.01 and $220.94. The current price stands at $219.93, placing the stock +0.9% above today's low and -0.5% off the high.
The AbbVie(ABBV)'s current trading volume is 29.44K, compared to an average daily volume of 5.47M.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $181.73.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $181.73.
ABBV News
AbbVie, the Healthcare sector company, was revisited by a Wall Street analyst on June 19. Analyst Evan Seigerman from BMO Capital maintained a Buy rating on the...
Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...
...
Analyst ratings
72%
of 32 ratingsMore ABBV News
AbbVie has agreed to buy Apogee Therapeutics for about $10.9 billion in cash Brian Snyder / Reuters AbbVie ABBV -2.14 %decrease; down pointing triangle has agr...
AbbVie (ABBV) and Apogee Therapeutics (APGE) announced they have entered into a definitive agreement under which AbbVie will acquire Apogee and its diverse pipe...
BTIG analyst Julian Harrison says AbbVie (ABBV) can leverage its existing dermatology channels and compete in atopic dermatitis beyond JAK inhibitors with an ac...
AbbVie is reportedly trying to buy a biotech company that is developing a promising atopic dermatitis drug for $10.9 billion in cash, according to a Financial T...
Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more conf...
AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's per...
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and AbbVie didn't make the cut. Grab the names FREE today . For income investo...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.